Certain Plant-Derived Recombinant Human Serum Albumins (“rHSA”) and Products Containing Same; Notice of Institution of Investigation, 6916-6917 [2021-01439]

Download as PDF 6916 Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices Certification of Plans, Specifications, and Site; (2) Form HUD–92544, Warranty of Completion of Construction; (3) Form HUD–NPMA– 99–A, Subterranean Termite Protection Builder’s Guarantee; and (4) Form HUD–NPMA–99–B, New Construction Subterranean Termite Service Record. These forms are currently required by FHA for maximum financing for FHA’s Title II Single Family forward mortgage programs and will align both the reverse and forward mortgage programs to ensure the property meet’s FHA’s minimum property standards while ensuring the home is safe, sound, and secure for the HECM borrower. Respondents (i.e., affected public): Business or other for profit. Estimated Number of Respondents: 2,375. Estimated Number of Responses: 59,375. Frequency of Response: Occasionally. Average Hours per Response: 2.54 hours. Total Estimated Burdens: 116,398.75. B. Solicitation of Public Comment jbell on DSKJLSW7X2PROD with NOTICES This notice is soliciting comments from members of the public and affected parties concerning the collection of information described in Section A on the following: (1) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond: Including through the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. (5) Ways to minimize the burden of the collection of information on those who are to respond, including the use of automated collection techniques or other forms of information technology. HUD encourages interested parties to submit comments in response to the proposed changes. Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35. Colette Pollard, Department Reports Management Officer, Office of the Chief Information Officer. [FR Doc. 2021–01515 Filed 1–22–21; 8:45 am] BILLING CODE 4210–67–P VerDate Sep<11>2014 18:31 Jan 22, 2021 Jkt 253001 INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–1238] Certain Plant-Derived Recombinant Human Serum Albumins (‘‘rHSA’’) and Products Containing Same; Notice of Institution of Investigation International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on December 16, 2020, under section 337 of the Tariff Act of 1930, as amended, on behalf of Ventria Bioscience Inc. of Junction City, Kansas. Supplements to the complaint were filed on December 16, and 22, 2020. The complaint, as supplemented, alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain plant-derived recombinant human serum albumins (‘‘rHSA’’) and products containing same by reason of infringement of certain claims of U.S. Patent No. 10,618,951 (‘‘the ’951 patent’’); and U.S. Patent No. 8,609,416 (‘‘the ’416 patent’’). The complaint further alleges that an industry in the United States exists as required by the applicable Federal Statute. The complaint also alleges violations of section 337 based on the importation into the United States, or in the sale of, certain plant-derived recombinant human serum albumins (‘‘rHSA’’) and products containing same by reason of false designation of origin, the threat or effect of which is to destroy or substantially injure an industry in the United States. The complainant requests that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders. ADDRESSES: The complaint, except for any confidential information contained therein, may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email EDIS3Help@usitc.gov. Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205– 2000. General information concerning SUMMARY: PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. FOR FURTHER INFORMATION CONTACT: Pathenia M. Proctor, The Office of Unfair Import Investigations, U.S. International Trade Commission, telephone (202) 205–2560. SUPPLEMENTARY INFORMATION: Authority: The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in section 210.10 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.10 (2020). Scope of Investigation: Having considered the complaint, the U.S. International Trade Commission, on January 14, 2021, ordered that— (1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine: (a) Whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain products identified in paragraph (2) by reason of infringement of one or more of claims 1–3 and 11–13 of the ’951 patent and claims 1–3, 5–7, 10, 12, 18–20, and 22–25 of the ’416 patent; and whether an industry in the United States exists as required by subsection (a)(2) of section 337; and (b) Whether there is a violation of subsection (a)(1)(A) of section 337 in the importation into the United States, or in the sale of, certain products identified in paragraph (2) by reason of false designation of origin. (2) Pursuant to section 210.10(b)(1) of the Commission’s Rules of Practice and Procedure, 19 CFR 210.10(b)(1), the plain language description of the accused products or category of accused products, which defines the scope of the investigation, is: Plant-derived recombinant human serum albumins (‘‘rHSA’’) and products containing the same, such as lyophilized powders and liquid suspensions primarily containing rHSA along with naturally-occurring plant expression by-products, such as plant heat shock proteins and/or plant fatty acids, as well as cell culture media supplements formulated with such rHSA products. (3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served: (a) The complainant is: Ventria Bioscience Inc., 2718 Industrial Drive, Junction City, Kansas 66441. E:\FR\FM\25JAN1.SGM 25JAN1 Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices jbell on DSKJLSW7X2PROD with NOTICES (b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served: Wuhan Healthgen Biotechnology Corp., No. 666 Gaoxin Avenue, East Lake High-Tech Development Zone, Wuhan, China, 430075 ScienCell Research Laboratories, Inc., 1610 Faraday Avenue, Carlsbad, California 92008 Aspira Scientific, Inc., 521 Cottonwood Drive, Suite 112, Milpitas, California 95035 eEnzyme LLC, 963 Featherstone Street, Gaithersburg, Maryland 20879 (c) The Office of Unfair Import Investigations, U.S. International Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and (4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge. Responses to the complaint and the notice of investigation must be submitted by the named respondent in accordance with section 210.13 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), as amended in 85 FR 15798 (March 19, 2020), such responses will be considered by the Commission if received not later than 20 days after the date of service by the complainant of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown. Failure of the respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent. INTERNATIONAL TRADE COMMISSION INTERNATIONAL TRADE COMMISSION [Investigation Nos. 701–TA–636 and 731– TA–1470 (Final)] Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest Wood Mouldings and Millwork Products From China; Revised Schedule for the Subject Investigations United States International Trade Commission. AGENCY: ACTION: DATES: Notice. January 13, 2021. FOR FURTHER INFORMATION CONTACT: Keysha Martinez (202–205–2136), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearingimpaired persons can obtain information on this matter by contacting the Commission’s TDD terminal on 202– 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (https:// www.usitc.gov). The public record for these investigations may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. On August 12, 2020, the Commission established a schedule for the conduct of the final phase of the subject investigations (85 FR 54593, September 2, 2020). In light of the federal holiday on January 20, 2021, the Commission is revising the final comments deadline to no later than 10 a.m., January 21, 2021. For further information concerning this proceeding, see the Commission’s notice cited above and the Commission’s Rules of Practice and Procedure, part 201, subparts A through E (19 CFR part 201), and part 207, subparts A and C (19 CFR part 207). SUPPLEMENTARY INFORMATION: Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to § 207.21 of the Commission’s rules. By order of the Commission. Issued: January 15, 2021. Lisa Barton, Secretary to the Commission. By order of the Commission. Issued: January 19, 2021. William Bishop, Supervisory Hearings and Information Officer. [FR Doc. 2021–01439 Filed 1–22–21; 8:45 am] [FR Doc. 2021–01532 Filed 1–22–21; 8:45 am] BILLING CODE 7020–02–P BILLING CODE 7020–02–P VerDate Sep<11>2014 18:31 Jan 22, 2021 Jkt 253001 6917 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 U.S. International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that the U.S. International Trade Commission has received a complaint entitled Certain Cellular Communications Infrastructure Systems, Components Thereof, and Products Containing Same, DN 3525; the Commission is soliciting comments on any public interest issues raised by the complaint or complainant’s filing pursuant to the Commission’s Rules of Practice and Procedure. FOR FURTHER INFORMATION CONTACT: Lisa R. Barton, Secretary to the Commission, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2000. The public version of the complaint can be accessed on the Commission’s Electronic Document Information System (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its internet server at United States International Trade Commission (USITC) at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission’s Electronic Document Information System (EDIS) at https://edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: The Commission has received a complaint and a submission pursuant to § 210.8(b) of the Commission’s Rules of Practice and Procedure filed on behalf of Ericsson Inc. and Telefonaktiebolaget LM Ericsson on January 15, 2021. The complaint alleges violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain cellular communications infrastructure systems, components thereof, and products containing same. The complaint names as respondents: Samsung Electronics Co. Ltd. of Korea and Samsung Electronics America, Inc. of Ridgefield Park, NJ. The complainant requests that the Commission issue a limited SUMMARY: E:\FR\FM\25JAN1.SGM 25JAN1

Agencies

[Federal Register Volume 86, Number 14 (Monday, January 25, 2021)]
[Notices]
[Pages 6916-6917]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-01439]


=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1238]


Certain Plant-Derived Recombinant Human Serum Albumins (``rHSA'') 
and Products Containing Same; Notice of Institution of Investigation

AGENCY: International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that a complaint was filed with the 
U.S. International Trade Commission on December 16, 2020, under section 
337 of the Tariff Act of 1930, as amended, on behalf of Ventria 
Bioscience Inc. of Junction City, Kansas. Supplements to the complaint 
were filed on December 16, and 22, 2020. The complaint, as 
supplemented, alleges violations of section 337 based upon the 
importation into the United States, the sale for importation, and the 
sale within the United States after importation of certain plant-
derived recombinant human serum albumins (``rHSA'') and products 
containing same by reason of infringement of certain claims of U.S. 
Patent No. 10,618,951 (``the '951 patent''); and U.S. Patent No. 
8,609,416 (``the '416 patent''). The complaint further alleges that an 
industry in the United States exists as required by the applicable 
Federal Statute. The complaint also alleges violations of section 337 
based on the importation into the United States, or in the sale of, 
certain plant-derived recombinant human serum albumins (``rHSA'') and 
products containing same by reason of false designation of origin, the 
threat or effect of which is to destroy or substantially injure an 
industry in the United States.
    The complainant requests that the Commission institute an 
investigation and, after the investigation, issue a limited exclusion 
order and cease and desist orders.

ADDRESSES: The complaint, except for any confidential information 
contained therein, may be viewed on the Commission's electronic docket 
(EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email 
[email protected]. Hearing impaired individuals are advised that 
information on this matter can be obtained by contacting the 
Commission's TDD terminal on (202) 205-1810. Persons with mobility 
impairments who will need special assistance in gaining access to the 
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be 
obtained by accessing its internet server at https://www.usitc.gov.

FOR FURTHER INFORMATION CONTACT: Pathenia M. Proctor, The Office of 
Unfair Import Investigations, U.S. International Trade Commission, 
telephone (202) 205-2560.

SUPPLEMENTARY INFORMATION: 
    Authority: The authority for institution of this investigation is 
contained in section 337 of the Tariff Act of 1930, as amended, 19 
U.S.C. 1337, and in section 210.10 of the Commission's Rules of 
Practice and Procedure, 19 CFR 210.10 (2020).
    Scope of Investigation: Having considered the complaint, the U.S. 
International Trade Commission, on January 14, 2021, ordered that--
    (1) Pursuant to subsection (b) of section 337 of the Tariff Act of 
1930, as amended, an investigation be instituted to determine:
    (a) Whether there is a violation of subsection (a)(1)(B) of section 
337 in the importation into the United States, the sale for 
importation, or the sale within the United States after importation of 
certain products identified in paragraph (2) by reason of infringement 
of one or more of claims 1-3 and 11-13 of the '951 patent and claims 1-
3, 5-7, 10, 12, 18-20, and 22-25 of the '416 patent; and whether an 
industry in the United States exists as required by subsection (a)(2) 
of section 337; and
    (b) Whether there is a violation of subsection (a)(1)(A) of section 
337 in the importation into the United States, or in the sale of, 
certain products identified in paragraph (2) by reason of false 
designation of origin.
    (2) Pursuant to section 210.10(b)(1) of the Commission's Rules of 
Practice and Procedure, 19 CFR 210.10(b)(1), the plain language 
description of the accused products or category of accused products, 
which defines the scope of the investigation, is: Plant-derived 
recombinant human serum albumins (``rHSA'') and products containing the 
same, such as lyophilized powders and liquid suspensions primarily 
containing rHSA along with naturally-occurring plant expression by-
products, such as plant heat shock proteins and/or plant fatty acids, 
as well as cell culture media supplements formulated with such rHSA 
products.
    (3) For the purpose of the investigation so instituted, the 
following are hereby named as parties upon which this notice of 
investigation shall be served:
    (a) The complainant is: Ventria Bioscience Inc., 2718 Industrial 
Drive, Junction City, Kansas 66441.

[[Page 6917]]

    (b) The respondents are the following entities alleged to be in 
violation of section 337, and are the parties upon which the complaint 
is to be served:

Wuhan Healthgen Biotechnology Corp., No. 666 Gaoxin Avenue, East Lake 
High-Tech Development Zone, Wuhan, China, 430075
ScienCell Research Laboratories, Inc., 1610 Faraday Avenue, Carlsbad, 
California 92008
Aspira Scientific, Inc., 521 Cottonwood Drive, Suite 112, Milpitas, 
California 95035
eEnzyme LLC, 963 Featherstone Street, Gaithersburg, Maryland 20879

    (c) The Office of Unfair Import Investigations, U.S. International 
Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and
    (4) For the investigation so instituted, the Chief Administrative 
Law Judge, U.S. International Trade Commission, shall designate the 
presiding Administrative Law Judge.
    Responses to the complaint and the notice of investigation must be 
submitted by the named respondent in accordance with section 210.13 of 
the Commission's Rules of Practice and Procedure, 19 CFR 210.13. 
Pursuant to 19 CFR 201.16(e) and 210.13(a), as amended in 85 FR 15798 
(March 19, 2020), such responses will be considered by the Commission 
if received not later than 20 days after the date of service by the 
complainant of the complaint and the notice of investigation. 
Extensions of time for submitting responses to the complaint and the 
notice of investigation will not be granted unless good cause therefor 
is shown.
    Failure of the respondent to file a timely response to each 
allegation in the complaint and in this notice may be deemed to 
constitute a waiver of the right to appear and contest the allegations 
of the complaint and this notice, and to authorize the administrative 
law judge and the Commission, without further notice to the respondent, 
to find the facts to be as alleged in the complaint and this notice and 
to enter an initial determination and a final determination containing 
such findings, and may result in the issuance of an exclusion order or 
a cease and desist order or both directed against the respondent.

    By order of the Commission.

    Issued: January 15, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021-01439 Filed 1-22-21; 8:45 am]
BILLING CODE 7020-02-P